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The great improvements in treatment for malignant disease in
childhood have led to a major increase in the number of long-term
survivors, reaching approximately 1 in every 900 young adults in
the USA by the year 2000 (Bleyer, 1990). Much of the improve-
ment in prognosis over the last 30 years has been due to the use of
effective multiagent chemotherapy. However, the late adverse
effects of this treatment may impair normal development and
maturation in children, cause lifelong ill health or disability, or
even lead to premature death (Hawkins and Stevens, 1996). The
rational development of preventive strategies depends on detailed
documentation and analysis of such toxicity.
Ifosfamide is an alkylating oxazaphosphorine with considerable
activity against a wide range of malignancies in both adults and
children (Zalupski and Baker, 1988; Pratt et al, 1989). It is used
increasingly in children since it may have advantages over
cyclophosphamide, its structural isomer, especially in the treat-
ment of Ewing’s sarcoma and rhabdomyosarcoma (Zalupski and
Baker, 1988; Pratt et al, 1989). However, the relative merits of
ifosfamide and cyclophosphamide have been the subject of
considerable debate (Shaw and Eden, 1990). Moreover, ifosfamide
may cause a characteristic pattern of nephrotoxicity in up to 30%
of children (Skinner et al, 1993). Once established, such damage is
persistent in most patients and may limit the ability to deliver
optimum potentially curative chemotherapy subsequently.
There is little information concerning the frequency of long-
term toxicity in children due to the paucity of follow-up studies.
Most well documented cases of severe nephrotoxicity have
occurred in children younger than 5 years old or in children
receiving higher cumulative ifosfamide doses (Skinner et al,
1993). A recent study reported that prior cisplatin treatment or
nephrectomy increased the risk of nephrotoxicity (Rossi et al,
1994). However, the relative importance of these and other
patient- and treatment-related risk factors for the development of
renal damage remains unclear.
In view of this data, the Late Effects Group of the United
Kingdom Children’s Cancer Study Group (UKCCSG) performed a
large and comprehensive study of renal function in children and
adolescents previously treated with ifosfamide in UKCCSG
centres. The aims were to investigate the prevalence, nature and
severity of chronic nephrotoxicity and the relevance of patient-
and treatment-related risk factors.
METHODS
Patients
Any child, adolescent or young adult, who had completed treat-
ment that included ifosfamide at a UKCCSG centre was eligible
for this cross-sectional study. Most patients had participated in the
UKCCSG ET-2 trial (Craft et al, 1998) (Ewing’s sarcoma [ES] of
bone), which opened to recruitment in 1987, or in the International
Society of Paediatric Oncology (SIOP) MMT-89 trial (rhabdo-
myosarcoma [RMS], soft tissue sarcoma [STS], extraosseous ES,
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or primitive neuroectodermal tumour [PNET]), which opened in
1989. Examination of the ET-2 and MMT-89 databases in 1991
revealed 119 surviving patients who had completed treatment with
ifosfamide-containing schedules at the 11 participating centres. Of
these, 91 (77%) were studied, but 17 (14%) were no longer avail-
able for study due to death or disease progression. Only 11 (9%)
potentially available patients were not studied. An additional 57
patients treated with ifosfamide using protocols other than ET-2 or
MMT-89 were studied at four of the participating centres. Twenty
of these patients have been included in a previous single centre
report (Skinner et al, 1996). In total, therefore, 148 patients were
studied. All but one received ifosfamide at their initial presenta-
tion, the other patient at first relapse.
Between 1992 and 1994 each patient was studied once prospec-
tively at a median of 6 (range 1–47) months after completion of
chemotherapy. Their median age at commencement of ifosfamide
treatment was 8.1 (range 0.1–25.2) years; 87 were male. Only one
was over 20 years of age.
The patients had been treated for RMS (65 patients), ES of bone
(59), other STS (16), extraosseous ES or PNET (seven), or
osteosarcoma (one). At commencement of ifosfamide treatment,
one patient with lower urinary tract obstruction had a raised serum
creatinine concentration; no other patient had clinical evidence 
of abnormal renal function (raised serum creatinine and/or
glomerular filtration rate [GFR] < 60 ml/min/1.73 m2). Although
no patient had undergone a nephrectomy, and none had renal infil-
tration by tumour, nine (including the child described above) had
urinary tract obstruction due to tumour at initial diagnosis of their
malignancy.
Treatment
Ifosfamide was given intravenously (i.v.) by continuous infusion
(6–9 g/m2 course–1 over 48–72 h) in 93 patients (including 12 in
whom a minority of courses were given by short (1–3 h) infu-
sions); by short (3 h) infusions (3 g/m2) on 3 successive days per
course (i.e. 9 g/m3 course–1) in 53 (including two in whom a
minority of courses were given by continuous infusion); or by both
schedules (each being used for an equal number of courses) in two.
The median total ifosfamide dose was 62.0 (6.1–165.0) g/m2,
given over a median of 8 (1–18) courses at 3-week intervals. All
patients received continuous i.v. hydration fluid as specified by the
treatment protocols, and all received a continuous i.v. infusion of
mesna, with additional boluses in nine. Radiotherapy was given to
a treatment volume that included renal tissue in four patients,
whilst other potentially nephrotoxic chemotherapy or i.v.
supportive treatment was given to 121 patients; three received
cisplatin, 107 aminoglycoside antibiotics, 44 vancomycin, 38
acyclovir and 24 standard amphotericin B.
Investigation and grading of nephrotoxicity
The study protocol was approved by the Joint Ethics Committee of
Newcastle Health Authority and the University of Newcastle upon
Tyne, and allowed assessment of glomerular, proximal and distal
renal tubular function (Skinner et al, 1991).
Glomerular function
GFR and serum creatinine concentration were measured. The
plasma clearance of 51chromium-labelled ethylenediaminetetra-
acetic acid (51Cr-EDTA) was recommended as the method of
choice to determine GFR, and was used in 116 patients. GFR was
measured from the plasma clearance of 99mtechnetium-labelled
diethylenetriaminepentaacetic acid (99mTc-DTPA) in a further
seven patients.
Proximal tubular function
Concentrations of electrolytes, creatinine, calcium, magnesium,
PO4 and glucose were measured in corresponding serum and urine
samples. The HCO3 was also measured. The fractional excretions
of sodium, potassium, calcium, magnesium, phosphate (FEp),
glucose (FEg) and urate, and the renal tubular threshold for
phosphate (Tmp/GFR) were calculated using standard formulae
(Skinner et al, 1991). The fractional excretion of a substance is the
percentage of the filtered load at the glomerulus that is subse-
quently excreted in the urine; an abnormally high fractional excre-
tion indicates reduced tubular reabsorption. Except for FEg, a
fractional excretion was considered abnormal only when elevated
in the presence of a reduced serum concentration. The Tmp/GFR
provides a measure of tubular phosphate reabsorption, being
reduced in the presence of impaired reabsorption.
Distal tubular function
The early morning urine pH and osmolality (EMUO) were
measured in the first sample voided on the day of study.
Achievement of a pH of ≤ 5.4 was taken to demonstrate normal
urinary acidification, and an EMUO of ³ 600 mOsm/kg to indicate
adequate urinary concentration. However, failure to reach these
values in a single early morning urine sample was not considered
proof of abnormal distal tubular function.
General aspects of renal function
The urinary concentrations of albumin and total protein were
measured, and expressed as ratios to the simultaneous urine creati-
nine concentration. Systolic blood pressure was also measured.
Nephrotoxicity grading
This was performed using a previously described system (Skinner
et al, 1993), which comprises measurement and scoring of 
GFR, Tmp/GFR, serum HCO3 and EMUO. These measures were
selected to give an overall measure of clinically important nephro-
toxicity due to ifosfamide, reflecting those aspects of toxicity with
the potential to cause morbidity or require chronic treatment. Each
was scored on a 0–4 scale, with 0 representing no, 1 mild, 2–3
moderate and 4 severe toxicity within each individual aspect of
renal damage. The individual scores are summated to give a
‘nephrotoxicity score’, potentially ranging from 0 to 16 (Table 1).
Other individual measures of nephrotoxicity were also graded on a
0–4 scale, and categorized as showing either no/mild toxicity
(grades 0 and 1; defined as serum sodium concentration 
³ 121 mmol/l in children < 12 months age or ³ 126 mmol/l for 
³ 1 year age, serum potassium ³ 3.0 mmol/l, serum calcium 
³ 1.95 mmol/l, and serum magnesium ³ 0.60 mmol/l for < 2 years
age or ³ 0.55 mmol/l for ³ 2 years age), or moderate/ severe toxi-
city (grades 2–4; defined as serum sodium, potassium, calcium or
magnesium concentrations lower than those listed above for
grades 0 and 1).
Normal ranges
The normal ranges for serum biochemistry and fractional excre-
tions were derived from investigation of 105 otherwise healthy1638 R Skinner et al
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children and adolescents (aged 0.1–16.6 years, 27 male) attending
the Royal Victoria Infirmary, Newcastle upon Tyne for investiga-
tion of a proven urinary tract infection (treated at least 1 month
previously), in whom clinical examination, renal and urinary tract
investigations and imaging proved to be normal (Table 2).
Previously outlined normal ranges were used for age- or sex-
dependent measures of toxicity, including biochemical variables
(serum concentrations of creatinine, bicarbonate, phosphate and
magnesium; and Tmp/GFR) (Skinner et al, 1991), and systolic
blood pressure (Children, 1987) (Table 2).
Table 1 Grading criteria for ifosfamide nephrotoxicity
Nephrotoxicity GFR Tmp/GFR HCO3 EMUO
< 12 months ³ 1 year < 12 months ³ 1 year
0 ³ 90 ³ 1.10 ³ 1.00 ³ 18.0 ³ 20.0 ³ 600 or normal response
to DDAVP (if tested)
1 60–89 0.90–1.09 0.80–0.99 15.0–17.9 17.0–19.9 500–599
2 40–59 0.70–0.89 0.60–0.79 12.0–14.9 14.0–16.9 400–499
3 20–39 No symptoms, but No symptoms, but No symptoms, but
0.60–0.69 0.50–0.59 10.0–11.9 12.0–13.9 300–399 with no response
to DDAVP (if tested)
4 ≤ 19 HR or myopathy or HCMA or NDI or
≤ 0.60 ≤ 0.50 ≤ 10.0 ≤ 12.0 ≤ 300 with no response
to DDAVP (if tested)
A score of 4 in an individual aspect of grading (e.g. GFR) constitutes severe toxicity in that aspect. Nephrotoxicity score (Ns) = sum of GFR + Tmp/GFR + HCO3
+ EMUO. 0 No nephrotoxicity, 1–3 Mild nephrotoxicity, 4–7 Moderate nephrotoxicity, ³ 8 Severe nephrotoxicity. GFR = glomerular filtration rate 
(ml/min/1.73 m2) (i.e. evaluating glomerular dysfunction); Tmp/GFR = renal tubular threshold for phosphate (mmol/l) (i.e. evaluating phosphaturia); 
HCO3 = blood bicarbonate concentration (mmol/l) (i.e. evaluating acidosis); EMUO = early morning urine osmolality (mOsm/kg) (i.e. evaluating impairment of
urine concentration); HR = hypophosphataemic rickets, HCMA = hyperchloraemic metabolic acidosis (i.e. renal tubular acidosis), NDI = nephrogenic diabetes
insipidus defined by clinical symptoms, signs, biochemical findings, and for HR, radiological abnormalities; DDAVP = DDAVP (desmopressin) test – a normal
response is defined by a urine osmolality ³ 800 mOsm/kg.
Table 2 Results of renal function investigations
Mean Range Normal No (%) of
range abnormal values
Glomerular
GFR (ml/min/1.73 m2) 93 44–189 90–175# 61/123 (50%)
Serum creatinine (mmol/l) 64 11–202 ≤ 55–70* 63/146 (47%)
Proximal tubular
Serum sodium (mmol/l) 138 130–146 137–144 26/146 (18%)
Serum potassium (mmol/l) 3.9 2.6–5.1 3.7–4.9 22/143 (15%)
Serum bicarbonate (mmol/l) 21.9 8.5–30.0 18–26* 22/95 (23%)
Serum phosphate (mmol/l) 1.25 0.49–1.96 0.90–1.85* 28/135 (21%)
Serum total calcium (mmol/l) 2.38 1.74–2.75 2.30–2.63 12/139 (9%)
Serum magnesium (mmol/l) 0.84 0.49–1.22 0.70–1.00*a 6/134 (4%)
Serum urate (mmol/l) 0.17 0.06–0.53 0.05–0.50* 5/93 (5%)
FEsodium (%) 0.9 0.02–3.7 0.2–1.9 2/103 (2%)
FEpotassium (%) 18.6 1.4–68.2 3.5–30.6 8/100 (8%)
FEphosphate (%) 20.7 1.5–117 2.2–20.2 19/103 (18%)
Tmp/GFR (mmol/l) 1.01 –0.18–1.93 0.99–1.93*b 45/103 (44%)
FEcalcium (%) 2.4 0.07–33.3 0.1–5.6 0/95
FEmagnesium (%) 4.9 0.5–13.5 1.1–9.1 0/96
FEglucose (%) 13.5 0.01–250 ≤ 0.05 52/59 (88%)
FEurate (%) 2.9 0.1–7.1 7.0–12.0d 3/52 (6%)
Distal tubular
pH 6.0 5.0–8.8 ≤ 5.4** 80/108 (74%)
Osmolality (mOsm/kg) 674 121–1264 ³ 600** 45/123 (37%)
General aspects
Urine albumin (mg/mmol creat) 13.4 1.0–40.4 < 10l 6/15 (40%)
Urine protein (mg/mmol creat) 139.0 0.1–707.0 < 20p 3/67 (4%)
*Normal range varies with age (Clayton et al, 1980; Brodehl et al, 1982; Skinner et al, 1991). **See text (Methods) (Skinner et al, 1991). Unless
otherwise stated, normal ranges are derived from investigation of 105 healthy children aged 0.1–16.6 years (see text). Some published normal
ranges were used, as listed below: # Barratt, (1974); a Clayton et al (1980); b Brodehl et al (1982); d Grantham and Chonko (1991); l Barratt et al
(1970); p Elises et al (1988). Except for FEglucose, an elevated FE value is taken to indicate proximal tubular toxicity only if the serum
concentration of the corresponding substance is below the normal range. A low FE value does not imply nephrotoxicity.
gradeStatistical analysis
The normality or otherwise of variables was examined using the
skewness and kurtosis tests. Multiple linear regression analysis
was used to evaluate total ifosfamide dose, age at start of treat-
ment, sex, ifosfamide schedule (short infusion or continuous infu-
sion) and exposure to other potential nephrotoxins, namely
aminoglycosides, vancomycin, acyclovir or amphotericin B (cate-
gorized as treatment at any time, or not, with each of these drugs)
as predictors for nephrotoxicity measured by GFR, serum PO4 and
HCO3 and Tmp/GFR. Initially all predictor variables were included
in multiple regression in a backward stepwise procedure and the
least significant variables (P > 0.2) were rejected. Only total dose
was found consistently to be significant (see Results); therefore
univariate linear regression was performed with total dose only.
The nephrotoxicity score had a highly skewed distribution.
Therefore, it was categorized as either none/mild (score 0–3) or
moderate/severe (score ³ 4), and stepwise logistic regression
analysis was performed in which the 8 independent variables
(dose, age, sex, schedule, and exposure to aminoglycosides,
vancomycin, acyclovir or amphotericin B) were used to predict
nephrotoxicity score. The above analyses were repeated after
exclusion of 16 patients with other major risk factors for the devel-
opment of nephrotoxicity (urinary tract obstruction at commence-
ment of ifosfamide treatment, radiotherapy to renal tissue,
cisplatin treatment). The absolute values of the individual
elements of nephrotoxicity (e.g. GFR) in patients in whom the
nephrotoxicity score could be calculated (i.e. patients with evalu-
able GFR, Tmp/GFR, serum HCO3 and EMUO) were compared
with those in patients in whom the score could not be calculated,
using unpaired t-tests for each variable. Analyses were performed
using STATA statistical software (StataCorp, 1997).
RESULTS
Those continuous measures of nephrotoxicity described below 
had an approximately normal distribution. Nephrotoxicity was
observed in a substantial proportion of patients (Table 2), although
considerable inter-individual variability was evident (Figures
1–2).
Glomerular function
GFR was below 90 ml/min/1.73 m2 in 61 of 123 evaluable patients
(50%), and below 60 ml/min/1.73 m2 (i.e. grade 2–4 toxicity) in 
11 (9%). The 51Cr-EDTA plasma clearance technique was used in
58 of these and the 99mTc-DTPA plasma clearance method in 
three. The serum creatinine concentration was elevated in 63 of
146 patients (43%). A statistically significant fall in GFR was
observed in 67 patients in whom it was measured (using the same
method) both at diagnosis and after completion of treatment 
(mean [95% confidence limits] fall 35.1 [22.1–47.9] ml/min/ 
1.73 m2; paired t-test, t = 8.96,  P < 0.001).
UKCCSG study of ifosfamide nephrotoxicity 1639
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Proximal tubular function
Hypophosphataemia was observed in 28 of 135 evaluable patients
(21%), acidosis in 22 of 95 patients (23%), hypokalaemia in 22 of
143 (15%), hyponatraemia in 26 of 146 (18%), hypocalcaemia in 12
of 139 (9%), hypomagnesaemia in six of 134 (4%) and hypouri-
caemia in five of 93 (5%). Seven per cent of evaluable patients had
grade 2–4 (moderate or severe) toxicity scores for serum PO4, and
8% for serum HCO3, but only 3% for serum potassium, 1% each for
serum calcium and magnesium, and none for serum sodium.
Phosphaturia was demonstrated by a reduced Tmp/GFR in 45 of
103 evaluable patients (44%), with grade 2–4 toxicity in 23 (22%).
Only 19 of these 103 children (18%) had a high FEp. Excessive
urinary excretion of other electrolytes was present in a smaller
proportion of patients, with high fractional excretions of potassium
in eight of 100 evaluable children, and of sodium in two of 103
(2%). The commonest urinary abnormality was glycosuria, shown
by a high FEg in 52 of 59 evaluable patients (88%). Only three of
52 evaluable patients (6%) had a high fractional excretion of urate.
Distal tubular function
The early morning urine was adequately acidified (pH ≤ 5.4) in
only 28 of 108 evaluable patients (26%), and concentrated
(EMUO  ³ 600 mOsm/kg) in 78 of 123 (63%).
General aspects of renal function
Although only three of 67 evaluable patients (4%) had an elevated
urine protein:creatinine concentration ratio, six of 15 (40%) had a
high urine albumin:creatinine concentration ratio. Six of 127
evaluable patients (5%) had severe systolic hypertension; all other
patients were normotensive.
The majority of patients with glomerular toxicity also had
evidence of tubular impairment. Of 44 fully evaluable patients
with GFR grade ³ 1 (i.e. mild or greater toxicity), only 15 (34%)
had grade 0 Tmp/GFR and HCO3. More strikingly, nearly all chil-
dren with tubular toxicity had glomerular damage. Of 40 fully
evaluable patients with grade ³ 1 Tmp/GFR and HCO3, only one
(3%) had grade 0 GFR.
Nephrotoxicity grading
The nephrotoxicity score was fully evaluable (i.e. GFR, Tmp/GFR,
HCO3 and EMUO all evaluable) in 76 patients. Of these, 17 (22%)
had no, 38 (50%) mild, 15 (20%) moderate and six (8%) severe
nephrotoxicity, using the definitions shown in Table 1. No signifi-
cant difference was seen in the severity of nephrotoxicity between
these patients and the other 72 in whom the nephrotoxicity score
was not fully evaluable. No child had grade 4 toxicity for GFR, but
ten of 103 (10%) had grade 4 toxicity for Tmp/GFR, one of 95
(1%) for HCO3, and five of 123 (4%) for EMUO.
Risk factors
GFR, serum PO4, serum HCO3 and Tmp/GFR
Multiple regression analysis revealed that only total dose exerted a
consistent significant effect (P < 0.05) on GFR, serum PO4 and
HCO3 and Tmp/GFR. Univariate linear regression analysis
revealed statistically significant and clinically important correla-
tions between total ifosfamide dose and GFR (P = 0.006) (Figure
1), serum PO4 (P < 0.001) and HCO3 (P < 0.001), and Tmp/GFR (P
< 0.001) (Figure 2) (Table 3). Higher doses were associated with
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greater toxicity. However, due to considerable inter-patient vari-
ability, no entirely safe dose limit was discernible, but children
receiving ³ 80 g/m2 suffered greater proximal tubular damage
(Figure 2, Table 4). The other predictor variables studied in the
multivariate analysis had no independent effect, with the excep-
tions of relationships between younger age at treatment and lower
serum HCO3 (P < 0.001), acyclovir exposure and lower Tmp/GFR
(P = 0.02), and amphotericin B exposure and lower serum PO4
(P = 0.049) (Table 3).
Nephrotoxicity score
Multiple logistic regression revealed that only total ifosfamide dose
had a significant predictive influence (P = 0.001) on nephrotoxicity
score (none/mild vs moderate/severe); other potential risk factors
had no significant effect (P > 0.1 in all cases). An increase in ifos-
famide dose of 50 g/m2 increased the risk of moderate/severe
(compared to no/mild) nephrotoxicity by an odds ratio of 6.8 (95%
confidence limits 2.7–16.9). The importance of ifosfamide dose in
determining the likelihood of no, mild, moderate or severe nephro-
toxicity is illustrated in Figure 3.
Exclusion of the 16 patients with other major risk factors for the
development of nephrotoxicity did not change the outcome of
these analyses – total dose remained the only consistently signifi-
cant predictor of nephrotoxicity.
DISCUSSION
Although early studies failed to reveal any evidence of nephro-
toxicity in children receiving ifosfamide (de Kraker and Voute, 1984;
Gasparini, 1986; Biron et al, 1987; Kellie et al, 1988; Demeocq et
al, 1989), subsequent reports described a characteristic pattern of
proximal renal tubular damage, often accompanied by glomerular
and sometimes by distal tubular impairment (Smeitink et al, 1988;
Burk et al, 1990; Skinner et al, 1990; Pratt et al, 1991; Suarez et al,
1991; Caron et al, 1992; Shore et al, 1992; De Schepper et al, 1993;
Arndt et al, 1994; Ashraf et al, 1994). Such toxicity persisted long
after discontinuation of ifosfamide treatment in many patients,
often presenting with clinical manifestations due to the Fanconi
syndrome (Skinner et al, 1993). It is now clear that there is much
inter-individual variability in the onset, nature and severity of renal
toxicity due to ifosfamide. Many children suffer little or no renal
toxicity, but a few are severely affected (Smeitink et al, 1988;
Skinner et al, 1990, 1993). Acute tubular toxicity may follow the
first course of treatment (Heney et al, 1989; Devalck et al, 1991), or
chronic glomerular and tubular damage may present many months
after completion of ifosfamide (Moncrieff and Foot, 1989; De
Schepper et al, 1991; Suarez et al, 1991; Caron et al, 1992).
The reported incidence of severe chronic nephrotoxicity in chil-
dren has varied widely from 1.4% (Pratt et al, 1991) to about 30%
(De Schepper et al, 1993), probably depending on the distribution
of risk factors amongst different patient groups and on the sensi-
tivity of the methods used to detect renal damage. The commonest
clinical sequelae of ifosfamide nephrotoxicity include hypophos-
phatemia, which may lead to rickets (Moncrieff and Foot, 1989;
Burk et al, 1990; Skinner et al, 1990; De Schepper et al, 1991;
Pratt et al, 1991; Suarez et al, 1991; De Schepper et al, 1993), and
renal tubular acidosis (Heney et al, 1989; Suarez et al, 1991), both
of which may impair growth (De Schepper et al, 1991).
Nephrogenic diabetes insipidus may occur (Smeitink et al, 1988;
Skinner et al, 1990). 
The degree of reversibility of ifosfamide nephrotoxicity remains
uncertain. Although partial improvement may occur, including reso-
lution of rickets without specific treatment (Van Gool et al, 1992) and
improvement in biochemical abnormalities in some children (Suarez
et al, 1991; Caron et al, 1992), there is only one published description
of complete recovery from severe, chronic glomerular and tubular
impairment in children (Ashraf et al, 1997). Indeed, there is evidence
that glomerular (Burk et al, 1990; Prasad et al, 1996) and tubular
(Caron et al, 1992) toxicity may progress over a period of months or
years following completion of ifosfamide treatment.
Several risk factors for the development of nephrotoxicity after
ifosfamide have been suggested, including age, the total dose of
ifosfamide received, the method of drug administration, previous
or concurrent treatment with cisplatin, prior nephrectomy and the
presence of pre-existing renal impairment or infiltration by tumour
(Skinner et al, 1993). Furthermore, quantitative inter-patient
variability in ifosfamide metabolism may determine individual
risk (Skinner et al, 1993).
Although ifosfamide nephrotoxicity may occur at any age
(Skinner et al, 1993), most published reports of severe toxicity
have been in young children, who may be more susceptible to
proximal tubular toxicity, (Suarez et al, 1991; Caron et al, 1992;
Shore et al, 1992; De Schepper et al, 1993; Skinner et al, 1993;
Raney et al, 1994), due to a combination of anatomical, biochem-
ical and physiological factors (Fetterman et al, 1965). Although
extensive renal damage has occurred after total ifosfamide doses
of between 12 and 60 g/m2 (Smeitink et al, 1988; Heney et al,
1989; Moncrieff and Foot, 1989; Burk et al, 1990; Devalck et al,
1991), several authors have suggested that children receiving
higher cumulative doses (> 60 or > 72 g/m2) have a greater risk of
nephrotoxicity (Bisogno et al, 1993; De Schepper et al, 1993;
Skinner et al, 1993; Raney et al, 1994).
Despite documented variability in ifosfamide metabolism with
different schedules, no published evidence is yet available which
shows convincingly that any one administration regiment of ifos-
famide and mesna is superior in terms of improved efficacy or
reduced toxicity (Skinner et al, 1993). Some studies have found an
increased incidence of severe ifosfamide nephrotoxicity in patients
who have also received cisplatin (Moncrieff and Foot, 1989; Pratt
et al, 1991; Shore et al, 1992; Rossi et al, 1994) or who had previ-
ously undergone unilateral nephrectomy (Burk et al, 1990; Rossi et
al, 1994). Furthermore, there are several case reports of severe
renal damage after ifosfamide treatment in patients with renal
infiltration by tumour (Bremner et al, 1974; Holoye et al, 1982), 
or those with pre-existing renal impairment (Wheeler et al, 1986;
Davies et al, 1989), but it is not known whether the overall
incidence of nephrotoxicity is increased in these patients.
Table 4 Total ifosfamide dose as a risk factor for the development of
proximal tubular toxicity
Total ifosfamide dose
≤ 79.9 (g/m2) ³ 80.0 (g/m2) P
Serum PO4 1.33 (0.03) 1.10 (0.04) < 0.001
Tmp/GFR 1.18 (0.03) 0.77 (0.06) < 0.001
Serum HCO3 23.1 (0.4) 20.3 (0.7) < 0.001
FEg 1.8 (0.7) 23.6 (8.8) 0.02
Results expressed as mean (standard error). P-values relate to unpaired 
t-tests between the two different dose groups.There is still much uncertainty about role of each of these risk
factors, especially age, dose and cisplatin treatment, but ascertain-
ment of the most important might enable prediction and careful
monitoring of ‘high risk’ patients or. A major aim of this study was
therefore to clarify which of the above risk factors was most
important in a large group of children and adolescents receiving
ifosfamide in standard treatment protocols in the UK.
The commonest abnormal finding was of proximal tubular toxi-
city in association with glomerular impairment. Fewer patients 
had isolated glomerular, and very few isolated tubular, damage.
Additional biochemical abnormalities most likely to be due to
proximal tubular toxicity were seen in a minority of patients, but
the magnitude of these latter abnormalities was considerably less
than that of the hypophosphataemia and acidosis.
The finding that GFR was reduced in 50% of patients demon-
strates that glomerular impairment is very common when accurate
measurements (e.g. radioisotopic plasma clearance methods) are
used. Although reports of chronic renal failure are very rare
(Sangster et al, 1984), this frequency of subclinical glomerular
damage leads to concern about the future prognosis for renal func-
tion in some of these patients. The glomerulotoxic nature of ifos-
famide was shown clearly by the mean fall of 35 ml/min/1.73 m2
in the 66 patients in whom GFR was measured before and after
chemotherapy.
The system of nephrotoxicity grading (Skinner et al, 1993)
employed in this study provided an objective overall measure of
the severity of clinically relevant nephrotoxicity, in contrast to
the more subjective score proposed previously by Caron et al
(1992). The demonstration that only 22% of 76 fully evaluable
patients had no nephrotoxicity, and that 28% had moderate or
severe clinically relevant toxicity, is therefore particularly
worrying. It might be argued that patients with severe toxicity
were more likely to be entered into this study, and to be evaluated
fully. However, this is unlikely to have been the case since no
selection bias within centres was apparent with respect to patient
entry. In total, 91% of the 119 potentially eligible patients identi-
fied at the start of the study were either studied or excluded due
to death or progressive disease. Furthermore, there was no signif-
icant difference in the severity of proximal tubular toxicity
between the 76 patients with fully evaluable nephrotoxicity
scores and the 72 without.
The analysis of risk factors for the development of ifosfamide
nephrotoxicity in this population of patients, none of whom had
undergone nephrectomy and only three of whom had received
cisplatin, has demonstrated clearly that total dose is the most
important risk factor. This is of great practical importance
because in many countries ifosfamide is seldom used in combina-
tion with cisplatin or in patients who have undergone unilateral
nephrectomy. Therefore total ifosfamide dose is probably more
generally relevant as a major risk factor than prior or concurrent
cisplatin treatment and nephrectomy. Although it is clear from
Figures 1 and 2 that the considerable inter-patient variability in
the severity of nephrotoxicity, even between patients receiving
similar doses, prevents definition of an entirely ‘safe’ dose limit,
Figure 3 demonstrates that no patients receiving < 84 g/m2
suffered severe, and only 20% moderate, nephrotoxicity; whilst of
those receiving > 119 g/m2, 33% suffered severe and 40%
moderate nephrotoxicity. Clearly, clinically significant nephro-
toxicity is relatively infrequent below 84 g/m2 but unacceptably
common above 119 g/m2.
Another important finding is that age is not a major independent
risk factor. The relevance of the statistically significant relation-
ship between younger age and lower serum HCO3 is uncertain
since healthy infants have lower serum HCO3 concentrations
(Skinner et al, 1991). However, caution is still necessary in
younger patients, in whom the consequences of nephrotoxicity,
including growth impairment, may be greater.
This is the largest published study of ifosfamide nephrotoxicity
in which investigations have been performed prospectively.
However, a few potential criticisms of the study may be made. In
particular, the multi-centre design might have led to bias in patient
selection. However, there was no evidence of such bias, and a
consistent investigatory protocol was used in all centres, incorpo-
rating well established and straightforward clinical investigations.
Some of these investigations have normal ranges that vary with
age, but this was accounted for in the analysis of the frequency of
toxicity. It is theoretically possible that the higher normal values 
of serum PO4 and of Tmp/GFR in younger children may have
obscured the importance of younger age as a risk factor for this
aspect of proximal tubular toxicity. However, there was no other
suggestion that age was a significant predictor of nephrotoxicity,
even with measures of renal function that do not vary significantly
over the age range studied (e.g. GFR, which is stable after the age
of 2 years).
Although ifosfamide administration schedule was included as a
predictor in the multiple regression model, this analysis may not
have been able to distinguish any potential independent effect of
schedule from that of the total ifosfamide dose received in view of
the close relationship between the schedule used and total dose
received. However, inspection of Figures 1 and 2 does not suggest
that schedule has any important independent influence. The
majority of patients studied had been exposed to other potential
nephrotoxic insults. Exclusion of 16 patients with the most impor-
tant potential risk factors (urinary tract obstruction, renal radio-
therapy, cisplatin) did not alter the results, and analysis of the
possible importance of exposure to other nephrotoxic drugs
(aminoglycosides, vancomycin, acyclovir, amphotericin B) did 
not suggest any consistent pattern of increased nephrotoxicity.
However, exposure to these drugs was only recorded as present 
or absent, so interpretation of their possible additive effects in
ifosfamide nephrotoxicity is limited.
The cross-sectional nature of the study is unlikely to have biased
the results significantly since there is no published evidence of
consistent important changes in the severity of chronic ifosfamide
nephrotoxicity with time after completion of treatment, and any
such changes would have been highly unlikely to produce system-
atically a spurious dose effect of the magnitude observed in this
study. In any case the occurrence of chronic nephrotoxicity at any
time after completion of treatment is of concern.
The results of this study suggest that future strategies to prevent
ifosfamide nephrotoxicity in children and adolescents should be
centred around dose limitation, but also imply that this approach,
whilst reducing the frequency of clinically significant nephrotoxi-
city, will not prevent all cases. It is possible that some of the inter-
patient variability in the severity of toxicity reflects corresponding
differences between individuals in the pharmacokinetics and
metabolism of ifosfamide, but this remains unproven (Boddy et al,
1996). Identification of such a relationship and its use to enable
prediction of the risk of subsequent nephrotoxicity clearly would
be of great value. An alternative approach of using the occurrence
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prediction of subsequent chronic toxicity is under investigation
(Skinner et al, 1994). Although it appears unlikely that different
ifosfamide schedules are associated with different risks of toxicity,
this issue should be addressed in a comparative study that includes
endpoints of efficacy as well as toxicity.
In conclusion, this large and comprehensive prospective study
has shown that moderate and severe nephrotoxicity are common
after ifosfamide treatment in children and adolescents, affecting
28% of patients. Multivariate analysis revealed that total ifos-
famide dose was the only significant risk factor for the develop-
ment of toxicity in this group of patients, only three of whom
received cisplatin. Although it was not possible to specify a clini-
cally realistic total dose below which toxicity was never observed,
use of doses below 84 g/m2 will reduce the frequency of clinically
significant nephrotoxicity.
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